News • ExoGrail

Prostate cancer: urine test could reduce biopsies

Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.

Photo
The researchers say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent.
Source: Scientific Animations, Inc.

They show how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or a biopsy. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.

Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School and also a visiting worker at the Earlham Institute, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise over-diagnosis and overtreatment whilst appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy. Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.”

The research team developed the new ExoGrail urine test by combining two biomarker sources - measurements of a protein-marker called EN2 and the levels of gene expression of 10 genes related to prostate cancer risk. It builds on previously developed tests called PUR and ExoMeth.

When the urine results were compared to biopsy results, the study showed that the test had successfully shown which patients had prostate cancer and which did not. The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial.

The findings show that using information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

Dr Brewer said: “Our new urine test not only shows whether a patient has prostate cancer, but it importantly shows how aggressive the disease is. This allows patients and doctors to select the correct treatment. And it has the potential to reduce the number of unnecessary biopsies by 35 per cent.”

Paul Villanti, executive director of programmes at Movember, said: “We are proud to have supported the development of the ExoGrail urine test as part of our Global Action Plan Urine Biomarker project. Having non-invasive tests which can accurately show how aggressive a man’s prostate cancer is not only reduces the number of men having to undergo painful biopsies, but also ensures that the right course of treatment for the patient is selected more quickly.”

Source: University of East Anglia

10.06.2021

Read all latest stories

Related articles

Photo

News • Treatment guidance

Metastatic prostate cancer comes in two forms

Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment.

Photo

News • Oncology

How cancer spreads in blood

A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a…

Photo

Article • Prostate pathological

A pathologist’s view of prostate diagnostics

Pathology is the gold standard of prostate diagnostics. Whilst the radiologist makes interpretations based on shadows and grey scale values visible on an image, the pathologist has the ‘fait…

Related products

Subscribe to Newsletter